Cargando…

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment

A more comprehensive understanding of how cells respond to drug intervention, the likely immediate signalling responses and how resistance may develop within different microenvironments will help inform treatment regimes. The nonreceptor tyrosine kinase SRC regulates many cellular signalling process...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dawson, John C., Munro, Alison, Macleod, Kenneth, Muir, Morwenna, Timpson, Paul, Williams, Robert J., Frame, Margaret, Brunton, Valerie G., Carragher, Neil O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895456/ https://www.ncbi.nlm.nih.gov/pubmed/34856074 http://dx.doi.org/10.1002/1878-0261.13151

Ejemplares similares

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424
por: Woodcock, Victoria K, et al.
Publicado: (2018)

Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase
por: Fraser, Craig, et al.
Publicado: (2016)

A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
por: Temps, Carolin, et al.
Publicado: (2021)

Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors
por: Beetham, Henry, et al.
Publicado: (2022)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2018)

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2022)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo
por: Fan, Fan, et al.
Publicado: (2023)

Kindlin-1 regulates IL-6 secretion and modulates the immune environment in breast cancer models
por: Webb, Emily R, et al.
Publicado: (2023)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling
por: Bolado-Carrancio, Alfonso, et al.
Publicado: (2021)

Diversity of Matriptase Expression Level and Function in Breast Cancer
por: Welman, Arkadiusz, et al.
Publicado: (2012)

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
por: Desar, Ingrid M. E., et al.
Publicado: (2012)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

The potential of Src inhibitors
por: Elias, Daniel, et al.
Publicado: (2015)

P04.24. Use of relaxation techniques and complementary and alternative medicine by adults with insomnia symptoms: results from a national survey
por: Bertisch, S, et al.
Publicado: (2012)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

Novel roles of PRK1 and PRK2 in cilia and cancer biology
por: Patel, Hitesh, et al.
Publicado: (2020)

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
por: Qu, Yiqing, et al.
Publicado: (2014)

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
por: Glen, Hilary, et al.
Publicado: (2011)

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Structure and Characterization of a Covalent Inhibitor of Src Kinase
por: Gurbani, Deepak, et al.
Publicado: (2020)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Structural and functional characterization of the divergent Entamoeba Src using Src inhibitor-1
por: López-Contreras, Luilli, et al.
Publicado: (2017)

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
por: Ferguson, Jennifer, et al.
Publicado: (2012)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery
por: Isherwood, Beverley, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_20hi0ok84q0imnv0lblj6croip